Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
about
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinomaRamucirumab in metastatic colorectal cancer: evidence to date and place in therapyProfile of ramucirumab in the treatment of metastatic non-small-cell lung cancerAngiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinomaSecond-line treatment of metastatic gastric cancer: Current options and future directionsClinical utility of ramucirumab in advanced gastric cancerCritical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancersAnti-angiogenic agents in metastatic colorectal cancerAngiogenesis in metastatic colorectal cancer and the benefits of targeted therapyTargeting angiogenesis in squamous non-small cell lung cancerAnti-vascular endothelial growth factor therapy in breast cancerDrugs derived from phage display: from candidate identification to clinical practiceGastric Cancer: New Drugs - New StrategiesThe dual role of tumor lymphatic vessels in dissemination of metastases and immune response developmentEvolution of ramucirumab in the treatment of cancer - A review of literatureShort-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapyTranslational imaging endpoints to predict treatment response to novel targeted anticancer agents.Comparative genomic analysis of primary and synchronous metastatic colorectal cancersPhase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors.Targeted inhibition of VEGF receptor 2: an update on ramucirumab.Targeting lymphatic vessel functions through tyrosine kinases.Have we overestimated the benefit of human(ized) antibodies?A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancerGene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceDifferential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environmentPhage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.Antibody phage display libraries: contributions to oncology.Molecular targeting to treat gastric cancer.Regorafenib: from bench to bedside in colorectal cancer.Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.Ramucirumab: preclinical research and clinical development.Ramucirumab: successfully targeting angiogenesis in gastric cancer.Aflibercept in the treatment of metastatic colorectal cancer.Clinical advances in the development of novel VEGFR2 inhibitors.Anti-angiogenic therapies for advanced esophago-gastric cancerImmunotherapy of brain cancers: the past, the present, and future directions.Targeting metastatic upper gastrointestinal adenocarcinomasCharacteristics of human Ewing/PNET sarcoma models.
P2860
Q26741530-F3C6B88D-54FD-4EFA-9B52-E7793AB1193CQ26745418-7D517D58-BB5E-4F79-96F1-DA0032C7BDE6Q26750715-327EF5AB-0FB2-4999-8FF6-354CCCC56C6FQ26775394-868FFDAF-B319-4878-8B64-6BE27B914808Q26777690-A06950B8-8205-439B-859E-9F9E0117907EQ26778027-030D38C9-5A91-4039-988E-13336F78CC4DQ26785665-0ACC74A8-28BE-465D-A96E-B5265FB4BFC9Q26801289-7599EA67-B793-4D27-8351-6423323A6F5FQ26801911-7CDA80D3-6696-4C8B-8C2F-2F5E25096B75Q26853604-D90C59FA-636C-49F5-BB82-5F1726C2B15AQ26861341-B100D869-DCCD-47D2-AB9E-B0E086C29E39Q26999473-4E4DC198-16BC-415A-9B32-68D83CA17ADCQ27007101-10720F18-D528-4D77-81C1-C689510EB8EFQ27028079-C9EBE777-7698-4DD1-9118-5071E4B0D62CQ28076945-1761C41C-C936-4772-9461-8123F1C56445Q28276412-6DA4B803-A0FF-40DB-9226-D9C6FD6AF5FBQ30240170-CA89DCAC-8C80-49BE-A95A-D52A404FE0B0Q30455612-53F5D162-9C62-479B-96E1-E70523EF0386Q30465097-80570794-4B0F-45E8-B35D-6F84DB2B9842Q31153211-0747DB62-A0C5-4AD5-97B0-99523ACF1A6CQ33793562-6B62D5BE-6A56-4A1B-93DB-F57CC7B1C97EQ34040956-30FDCE8F-C41E-4D57-8FFA-0D4B1AD749A3Q34078275-C0C36D98-B886-4F2A-9D11-8946D7684101Q34142714-9611C0A6-D2A9-4A20-87C8-BB465B27115CQ34194044-8D2FE1C7-E306-4864-84A5-C000CFA972B3Q34245416-07FE3796-8C1E-4CC8-A573-B733D73EB529Q34268230-6DBDE881-0DF9-44A3-A2D1-0882EA400649Q34273411-BDDE58B9-98A6-4A82-AFBA-3FD54F2B5852Q34323991-0D041B6E-C273-45D4-861E-0A2BA12E2AA7Q34326593-3AE7E2EC-F4F6-47B7-8EE4-26A0C0832697Q34343524-0845F8C0-7D33-4A07-811A-B6A0C74B6FABQ34385537-3F0F604C-F992-495D-A08F-CE10A7409127Q34446310-AD1FE564-142A-409E-AED0-60A6A91AB980Q34616558-2482D223-3A89-4245-AA52-E83C0F28D6FFQ34635176-37843436-88D8-4C0E-B587-F73BA55FC429Q34658366-EFF30211-7183-4957-9C28-4D160C0AE495Q34686222-A679F0D1-DF32-4493-AA9D-B0FBEF882938Q34701587-5B097443-69B8-44BB-A1AD-C5B1CB62ADE1Q35000785-0094497F-B777-4C97-94D0-4BADB524841FQ35008659-C1EADD01-E386-4B87-825F-704CDEFBDE0B
P2860
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase I pharmacologic and biol ...... lial growth factor receptor-2.
@ast
Phase I pharmacologic and biol ...... lial growth factor receptor-2.
@en
type
label
Phase I pharmacologic and biol ...... lial growth factor receptor-2.
@ast
Phase I pharmacologic and biol ...... lial growth factor receptor-2.
@en
prefLabel
Phase I pharmacologic and biol ...... lial growth factor receptor-2.
@ast
Phase I pharmacologic and biol ...... lial growth factor receptor-2.
@en
P2093
P2860
P921
P356
P1476
Phase I pharmacologic and biol ...... lial growth factor receptor-2.
@en
P2093
Cindy O'Bryant
D Ross Camidge
E Gabriela Chiorean
Eric K Rowinsky
Hagop Youssoufian
Jennifer L Spratlin
Laura Q M Chow
Matthew Eadens
P2860
P304
P356
10.1200/JCO.2009.23.7537
P407
P577
2010-01-04T00:00:00Z